Patient Outcomes and PIK3CA Mutations
Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, discusses patient outcomes associated with PIK3CA mutations.
Clinical Pearls
Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, discusses patient outcomes associated with PIK3CA mutations.
- A number of studies have analyzed the outcomes of patients with a PIK3CA mutation.
- Preclinical data suggest the PIK3CA mutation may make tumors resistant to trastuzumab.
- Trastuzumab-naïve patients with HER2 amplification and a PIK3CA mutation seem to do better than those who do not. Patients with a PIK3CA mutation who are treated with trastuzumab seem to do worse.
- Patients with a PIK3CA mutation have a lower chance of having a pathologic complete response.
Jhaveri Compares Safety and Duration of Adjuvant CDK4/6 Inhibitors in HR+ Breast Cancer
December 22nd 2024During a Case-Based Roundtable® event, Komal Jhaveri, MD, FACP, discussed dosing and toxicity concerns with the approved CDK4/6 inhibitor regimens used in the adjuvant setting for patients with hormone receptor–positive breast cancer.
Read More
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
